EPO and chronic kidney disease: Experimental studies have highlighted the promise of renoprotective effect of exogenous erythropoietin (EPO) therapy in various CKD models6, including remnant kidney7, diabetic nephropathy8, ischemia-reperfusion injury9, and chronic allograft injury of transplant kidney10.